Advaxis receives notice of allowance from USPTO for cancer immunotherapy platform technology

The patent with the latest date of expiry is 2030, without taking into account patent term extension.

The three patent applications allowed by the USPTO cover composition of matter and methods of use for combining the Advaxis proprietary immunogenic but non-toxic recombinant tLLO fused to full and partial antigens of particular interest in the treatment of multiple cancers, including B-cell lymphoma in both humans and animals.

Additional patent applications also allowed by the USPTO encompass a method of use targeting multiple critical structural and identifying elements associated with B-cells and B-cell lymphomas and allow targeting of multiple structural peptides at the same time.

Also allowed separately are composition of matter and methods of use to accommodate the targeting of Advaxis treatments toward factors that are essential for tumors or metastases to form new blood vessels (angiogenesis) or that are expressed by tumor blood vessels. A method of use is allowed where multiple targets associated with angiogenesis can be targeted at the same time in animals as well as humans. These include, but are not limited to, HER2 and VEGFr2.

Advaxis chief scientific officer Dr. Robert Petit noted that these additional patents will allow us to expand the development of our immunotherapies to not only address existing tumors, but to also target factors expressed by tumors to establish blood vessels.

"Our immunotherapy has already shown clinical activity in treating cervical cancer in women and bone cancer in pet dogs, and preclinical activity in multiple potential indications, including head and neck, anal, prostate, and breast cancers. These patents indicate growth of our ongoing program to further expand our intellectual property portfolio as we continue to develop Advaxis immunotherapies to treat multiple cancers," Dr Petit added.